IK

Inhibikase Therapeutics IncNASDAQ IKT Stock Report

Last reporting period 30 Jun, 2024

Updated 26 Nov, 2024

Last price

Market cap $B

0.009

Micro

Exchange

XNAS - Nasdaq

View Section: Company Analysis

Inhibikase Rating

IK

IKT stock rating score is -1/100. Inhibikase is aExtremely Risky Investment.

The in-depth assessment covers such aspects as the profitability and solvency of the company, management efficiency, and growth sustainability. Our rating serves as an answer to whether the company`s shares are generally reasonable for purchase. The higher company rating score is, the more stock is attractive for investment.

Eyestock Rating

Last update 26.08.2024

-1/100

Low score

Rating Breakdown

  • Profitability score

    -25

    /25

  • Solvency score

    45

    /25

  • Efficiency score

    -25

    /25

  • Stability score

    5

    /25

Inhibikase Therapeutics Inc Rewards and Warnings

The assessment of the quality of a business is based on quantitative analysis of 10 key financials taken from the company's statements. Pay close attention to the cons, if any, before making a decision.

Financial

Check

Value

Net Profit Margin

-22984 %

Earnings quality

Gross Margin

Inhibikase Therapeutics Inc's Historical Rating

How has the company's valuation changed in the past?

A quick analysis will help you understand how stable financial indicators are overall.


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Discover High-rated Companies


View Section: Valuation